Internal Battle Results in Resignations for Anzu Special Acquisition Corp I
by Kristi Marvin on 2022-08-04 at 8:51pm

It’s one thing to negotiate with a target company, but quite another when you have to negotiate with your own team.  For Anzu Special Acquisition Corp. I (NASDAQ:ANZU), which filed an 8-K this afternoon, it appears that internal disagreements in regards to strategy have resulted in the loss of their CFO, General Counsel & Secretary, Chairman of the Board, and a Director, all of which have resigned.

As to who is left on the ANZU team, Dr. Whitney Haring-Smith, the CEO and director of ANZU, will continue to lead the team along with directors Priya Cherian Huskins and Susan J. Kantor.

Nonetheless, it’s important to note that Dr. Haring-Smith’s firm, Anzu Partners (for which the SPAC is named), focuses on early venture stage and growth companies. Today’s filing noted in the resignations that at issue was the targets the company was evaluating as well as the current market conditions.

But to give better context, let’s review the timeline of resignations.

First, on July 29, John W. Joy, the CFO, resigned with the reason given as “changes in direction for the Company, including in the targets that the Company is evaluating.”

On the same day, July 29, Peter J. Ganz, the General Counsel and Corporate Secretary of ANZU, also resigned and also noted “changes in direction for the Company, including in the targets that the Company is evaluating.”  However, cost cutting by the Company was also cited.

Then Teresa A. Harris, a Director, notified the company of her resignation, also on July 29.

And finally, on July 31, William Wulfsohn, the Chairman of the Board, gave his notice of resignation as well.

Nonetheless, both Teresa Harris and Williamn Wulfsohn stated that their resignations were a result of:

“…their disagreement with Company decisions and process leading to the resignations of Mr. Joy and Mr. Ganz and the resulting loss to the Company of the expertise of these two key executives; their disagreement with the nature of and approach to potential acquisition candidates the Company was considering in the context of changes in market conditions (both generally and for special purpose acquisition companies) and the approaching deadline for completing a business combination; and their disagreement with the Company’s continued pursuit of a specific business combination transaction.”

Typically we’re not given much information when an executive or board member leaves a company. For the most part, these usually say they are due to “personal reasons” or to “pursue other opportunities”. The ANZU resignations on the other hand give quite a bit of information and are pretty strongly worded.

Clearly, there is a disagreement regarding the “continued pursuit” of a specific transaction that the “resignees” do not want to pursue, nor think viable in today’s macroeconomic climate.  Furthermore, they note the “approaching completion deadline” implying that they’d rather be looking elsewhere instead of trying to run up a down escalator with the clock ticking.

ANZU still has seven months left until its March 4, 2023 deadline, but as we’ve seen, time elapses rapidly in SPACland. In fact, most teams will tell you there is an element of Einsteinian time distortion when trying to complete a SPAC. I.e., time goes twice as fast the closer you get to your deadline, while simultaneously slowing down to half speed at the SEC. These are the laws of SPAC physics.

In the meantime, ANZU is now not in compliance with Nasdaq’s listing standards since it requires the Audit Committee to be composed of at least three independent directors. However, ANZU is entitled to a cure period to regain compliance. As a result we should see further 8-Ks announcing an additional director or directors in the coming weeks.

 

Internal Battle Results in Resignations for Anzu Special Acquisition Corp I
Recent Posts
by Nicholas Alan Clayton on 2025-07-01 at 11:33am

Ribbon (NASDAQ:RIBB) has entered into a definitive agreement to combine with Japanese biotech firm DRC Medicine at a pro forma equity value of $422 million. Tokyo-based DRC Medicine manufactures reusable anti-bacterial and anti-allergen wearables and aims to go deeper into the medical device and pharmaceutical space. Transaction Overview Ribbon is expected to provide $50.4 million...

by Henrique Santa Rosa, CFA on 2025-07-01 at 11:09am

In June 2025, the SPAC market was marked by a notable rise in meeting delays, with adjournments and postponements playing a central role in extension activity, as sponsors navigated a more cautious market environment. Still, several SPACs secured shareholder approvals, and seven business combinations were completed during the month. At the same time, IPO issuance...

by Kristi Marvin on 2025-07-01 at 8:42am

An In-Depth Look at SPAC Activity Through the Second Quarter & First Half 2025 Below is a summary of the first half of 2025 SPAC market. If you’d like a pdf copy, you can access the link HERE. Q2 kicked off in chaos. President Trump’s shifting and often contradictory tariff announcements sent markets reeling, driving...

by Nicholas Alan Clayton on 2025-07-01 at 8:25am

At the SPAC of Dawn The market is set to be showered with new SPACs today as three more SPACs priced their IPOs overnight, bringing 2025’s total to 66, already surpassing the full-year total of 2024. After hours, Ribbon (NASDAQ:RIBB) also added a new SPAC deal to June’s tally just under the wire, bringing the...

by Nicholas Alan Clayton on 2025-06-30 at 9:04pm

NMP Acquisition Corp. (NASDAQ:NMPAU) announced the pricing of its $100 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “NMPAU”, Tuesday, July 1, 2025. The new SPAC plans to combine with a target company that has a resilient business model with potential to scale up revenue. NMP’s management...

logo

Copyright © 2025 SPACInsider, Inc. All Rights Reserved